Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IAVI P001: A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine

Next Previous
Trial Profile

IAVI P001: A Phase I Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Safety and Immunogenicity of TBC-M4, a multigenic MVA HIV Vaccine vs ADVAX, a multigenic DNA HIV Vaccine followed by TBC-M4, a multigenic MVA HIV Vaccine

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADVAX (Primary) ; HIV vaccine-TBC M4 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions

Most Recent Events

  • 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India
  • 27 Aug 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top